Table 2.

Inhibitory effects of short-term treatment of topical garcinol on cell proliferation and aberrant AA metabolism in DMBA-treated hamster cheek pouch

Group	Treatment	No	Body weight (g)	No. of hyperplasia	No. of dysplasia	Inflammatory cells (/mm2)	BrdU-labeling index	LTB4 (pg/mg)
1A	Negative control	3	162.27±23.44	-	-	47.78±19.73**	2.49±1.73**	2.75±0.54*
1B	DMBA	6	147.17±9.66	5.17±1.32	5.00±2.00	320.51±155.88	4.26±2.21	6.16±4.16
1C	DMBA+ 0.5mM Garcinol	6	154.00±10.99	3.67±0.82*	2.83±0.98**	197.72±83.77**	3.79±1.03	1.50±0.70**
1D	DMBA + 5mM Garcinol	6	148.50±14.56	3.50±1.05**	3.17±1.16*	184.39±64.16**	3.30±1.37*	0.86±0.76**
1E	DMBA + 50mM Garcinol	6	141.67±9.18	3.00±1.89**	2.00±0.89**	100.41±52.53**	3.01±1.78**	1.59±2.38**

^*P <0.05 as compared with Group 1B

^**P<0.01 as compared with Group 1B.